Uso do biomarcador renal dimetilarginina simétrica no diagnóstico precoce da insuficiência renal

Abstract

Kidney disease is commonly found in the small animal clinic, but its diagnosis often becomes late. Therefore, currently research by biomarkers More sensitive kidneys have been the focus of studies, in order to provide an early diagnosis, allowing an appropriate therapy for each patient in addition to improving the quality of life. The renal biomarker called Symmetrical Dimethylarginine (SDMA) has been showing significant early results for the diagnosis of kidney disease, being able to detect kidney damage when less than 50% of the function is compromised. The present work aims to address the use of this biomarker considered a great ally for the diagnosis of kidney disease.